Jazz Pharmaceuticals (JAZZ) Q1 2024 Annual Earnings
JAZZ·Reported May 1, 2024·After market close
Jazz Pharmaceuticals reported Q1 2024 revenue of $902.0M, missed analyst consensus of $954.0M by $52.0M. Diluted EPS came in at $2.68, missed the $4.14 consensus by $1.46.
Revenue
$902.0Mmissed by $52.0M
Consensus: $954.0MDiluted EPS
$2.68missed by $1.46
Consensus: $4.14
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Jazz Pharmaceuticals's Q1 2024 earnings report.
Jazz Pharmaceuticals (JAZZ) reported Q1 2024 earnings on May 1, 2024 after market close.
Jazz Pharmaceuticals reported revenue of $902.0M and diluted EPS of $2.68 for Q1 2024.
Revenue missed the consensus estimate of $954.0M by $52.0M. EPS missed the consensus estimate of $4.14 by $1.46.
You can read the 10-K/A periodic report (0001232524-24-000022) directly on SEC EDGAR. The filing index links above go to sec.gov.